Original Article
  

Evaluation of Interleukin-21, 23 and 27 mRNA Expression and Protein Level in Liver Transplant Patients

Abstract

Cytokines have prominent roles in activating of different T cells and shifting the immune response, in this study the role of three cytokines (IL-21, IL-23 and IL-27) is investigated in the liver transplant rejection. Three EDTA-treated blood samples were collected from each liver transplanted patient in 1st, 4th and 7th day of post-transplantation. The expression level of the mentioned cytokines was determined using real-time PCR for all samples. Also, the serum levels of cytokines were determined using ELISA tests. In acute rejection (AR) group (51 patients), mRNA expression pattern of IL-21and IL-23 showed a steady increase, but this pattern was converse for IL-27. Our results in non-acute rejection (non-AR) group (54 patients) showed an elevation in day 4 and then a decrease in day 7 for IL-21 and IL-23 genes. This pattern was converse again for IL-27 gene. In comparison between the two groups, in all 3 sampling times the mean of mRNA expression level of IL-21 and IL-23, showed an increase in AR group which this increase was significant for IL-21 in the 3rd (p=0.007) and for IL-23 in 2nd (p=0.048) and 3rd (p=0.049) sampling time, but the pattern of mRNA expression for IL-27 was contrary to the results of IL-21 and IL-23. Furthermore, ELISA technique also, showed the serum level changes the same as cytokines. In this study IL-21 and IL-23 showed pro-inflammatory properties in the liver transplant rejected patients. Also, IL-27 having different expression pattern, showed anti-inflammatory behavior which needs more considerations in future.

 

1. Afshari A, Yaghobi R, Karimi MH, Darbooie M, Azarpira N. Interleukin-17 gene expression and serum levels in acute rejected and non-rejected liver transplant patients. Iran J Immunol 2014; 11(1):29–39.

2. Xie X, Ye Y, Zhou L, Xie H, Jiang G, Feng X, et al. Th17 promotes acute rejection following liver transplantation in rats. J Zhejiang Univ Sci B 2010; 11(11):819–27.

3. Atalar K, Afzali B, Lord G, Lombardi G. Relative roles of Th1 and Th17 effector cells in allograft rejection. Curr Opin Organ Transplant 2009; 14(1):23–9.

4. Strengell M, Julkunen I, Matikainen S. IFN-alpha regulates IL-21 and IL-21R expression in human NK and T cells. J Leukoc Biol 2004; 76(2):416–22.

5. Li X. The common gammac-cytokines and transplantation tolerance. Cell Mol Immunol 2004; 1(3):167–72.

6. He H, Wisner P, Yang G, Hu H-M, Haley D, Miller W, et al. Combined IL-21 and low-dose IL-2 therapy induces anti-tumor immunity and long-term curative effects in a murine melanoma tumor model. J Transl Med 2006; 4(1):24.

7. Baan CC, Balk AHMM, Dijke IE, Korevaar SS, Peeters AMA, de Kuiper RP, et al. Interleukin-21: an interleukin-2 dependent player in rejection processes. Transplantation 2007; 83(11):1485–92.

8. Hecker A, Kaufmann A, Hecker M, Padberg W, Grau V. Expression of interleukin-21, interleukin-21 receptor alpha and related type I cytokines by intravascular graft leukocytes during acute renal allograft rejection. Immunobiology 2009; 214(1):41–9.

9. Zelante T, De Luca A, Bonifazi P, Montagnoli C, Bozza S, Moretti S, et al. IL-23 and the Th17 pathway promote inflammation and impair antifungal immune resistance. Eur J Immunol 2007; 37(10):2695–706.

10. Vaknin-Dembinsky A, Balashov K, Weiner HL. IL-23 is increased in dendritic cells in multiple sclerosis and down-regulation of IL-23 by antisense oligos increases dendritic cell IL-10 production. J Immunol 2006; 176(12):7768–74.

11. Fábrega E, López-Hoyos M, San Segundo D, Casafont F, Pons-Romero F. Changes in the serum levels of interleukin-17/interleukin-23 during acute rejection in liver transplantation. Liver Transpl 2009; 15(6):629–33.

12. Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedgwick JD, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005; 201(2):233–40.

13. Chen Y, Langrish CL, McKenzie B, Joyce-Shaikh B, Stumhofer JS, McClanahan T, et al. Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis. J Clin Invest 2006; 116(5):1317–26.

14. McLaughlin M, Alloza I, Quoc HP, Scott CJ, Hirabayashi Y, Vandenbroeck K. Inhibition of Secretion of Interleukin (IL)-12/IL-23 Family Cytokines by 4-Trifluoromethyl-celecoxib Is Coupled to Degradation via the Endoplasmic Reticulum Stress Protein HERP. J Biol Chem 2010; 285(10):6960–9.

15. Carvalho A, Cunha C, Di Ianni M, Pitzurra L, Aloisi T, Falzetti F, et al. Prognostic significance of genetic variants in the IL-23/Th17 pathway for the outcome of T cell-depleted allogeneic stem cell transplantation. Bone Marrow Transplant 2010; 45(11):1645–52.

16. Fábrega E, López-Hoyos M, San Segundo D, Casafont F, Pons-Romero F. Changes in the serum levels of interleukin-17/interleukin-23 during acute rejection in liver transplantation. Liver Transplant 2009; 15(6):629–33.

17. Kopp T, Lenz P, Bello-Fernandez C, Kastelein RA, Kupper TS, Stingl G. IL-23 production by cosecretion of endogenous p19 and transgenic p40 in keratin 14/p40 transgenic mice: evidence for enhanced cutaneous immunity. J Immunol 2003; 170(11):5438–44.

18. Schneider R, Yaneva T, Beauseigle D, El-Khoury L, Arbour N. IL-27 increases the proliferation and effector functions of human naïve CD8+ T lymphocytes and promotes their development into Tc1 cells. Eur J Immunol 2011; 41(1):47–59.

19. Wong CK, Chen DP, Tam LS, Li EK, Yin YB, Lam CWK. Effects of inflammatory cytokine IL-27 on the activation of fibroblast-like synoviocytes in rheumatoid arthritis. Arthritis Res Ther 2010; 12(4):R129.

20. Mittal A, Murugaiyan G, Beynon V, Hu D, Weiner HL. IL-27 induction of IL-21 from human CD8+ T cells induces granzyme B in an autocrine manner. Immunol Cell Biol 2012; 90(8):831–5.

21. Stumhofer JS, Hunter CA. Advances in understanding the anti-inflammatory properties of IL-27. Immunol Lett 2008; 117(2):123–30.

22. Le Texier L, Thebault P, Carvalho-Gaspar M, Vignard V, Merieau E, Usal C, et al. Immunoregulatory function of IL-27 and TGF-β1 in cardiac allograft transplantation. Transplantation 2012; 94(3):226–33.

23. Barrie AM, Plevy SE. The interleukin-12 family of cytokines: Therapeutic targets for inflammatory disease mediation. Clin Appl Immunol Rev 2005; 5(4):225–40.

24. Demetris AJ, Batts KP, Dhillon AP, Ferrell L, Fung J GS. Banff schema for grading liver allograft rejection: An international consensus document. Hepatology 1997; 25(3):658–63.

25. Scheller J, Schuster B, Hölscher C, Yoshimoto T, Rose-John S. No inhibition of IL-27 signaling by soluble gp130. Biochem Biophys Res Commun 2005; 326(4):724–8.

26. Wei L, Laurence A, Elias KM, O’Shea JJ. IL-21 is produced by Th17 cells and drives IL-17 production in a STAT3-dependent manner. J Biol Chem 2007; 282(48):34605–10.

27. Yang L, Anderson DE, Baecher-Allan C, Hastings WD, Bettelli E, Oukka M, et al. IL-21 and TGF-beta are required for differentiation of human T(H)17 cells. Nature 2008; 454(7202):350–2.

28. Xie A, Buras ED, Xia J, Chen W. The Emerging Role of Interleukin-21 in Transplantation. J Clin Cell Immunol 2012; Suppl 9(2):1–7.

29. Teng MWL, Andrews DM, McLaughlin N, von Scheidt B, Ngiow SF, Möller A, et al. IL-23 suppresses innate immune response independently of IL-17A during carcinogenesis and metastasis. Proc Natl Acad Sci U S A 2010; 107(18):8328–33.

30. Ha S-J, Kim D-J, Baek K-H, Yun Y-D, Sung Y-C. IL-23 induces stronger sustained CTL and Th1 immune responses than IL-12 in hepatitis C virus envelope protein 2 DNA immunization. J Immunol 2004; 172(1):525–31.

31. Hölscher C. The power of combinatorial immunology: IL-12 and IL-12-related dimeric cytokines in infectious diseases. Med Microbiol Immunol 2004; 193(1):1–17.

32. Parham C, Chirica M, Timans J, Vaisberg E, Travis M, Cheung J, et al. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. J Immunol 2002; 168(11):5699–708.

33. Lupardus PJ, Garcia KC. The Structure of Interleukin-23 Reveals the Molecular Basis of p40 Subunit Sharing with Interleukin-12. J Mol Biol 2008; 382(4):931–41.

34. Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedgwick JD, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005; 201(2):233–40.

35. Kastelein RA, Hunter CA, Cua DJ. Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammation. Annu Rev Immunol 2007; 25(1):221–42.

36. Yoshida S, Haque A, Mizobuchi T, Iwata T, Chiyo M, Webb TJ, et al. Anti-type V collagen lymphocytes that express IL-17 and IL-23 induce rejection pathology in fresh and well-healed lung transplants. Am J Transplant 2006; 6(4):724–35.

37. Batten M, Ghilardi N. The biology and therapeutic potential of interleukin 27. J Mol Med 2007; 85(7):661–72.

38. Hunter CA. New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions. Nat Rev Immunol 2005; 5(7):521–31.

39. Moon S-J, Park J-S, Heo Y-J, Kang C-M, Kim E-K, Lim M-A, et al. In vivo action of IL-27: reciprocal regulation of Th17 and Treg cells in collagen-induced arthritis. Exp Mol Med 2013; 45(10):e46.

Files
IssueVol 17, No 4 (2018) QRcode
SectionOriginal Article(s)
DOI https://doi.org/10.18502/ijaai.v17i4.89
PMID30537793
Keywords
Graft rejection Interleukin-21 Interleukin-23 Interleukin-27 Liver Transplantation
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Afshari A, Yaghobi R, Azarpira N, Gerami Zadeh B, Malek Hosseini SA, Darbouy M, Karimi MH. Evaluation of Interleukin-21, 23 and 27 mRNA Expression and Protein Level in Liver Transplant Patients. Iran J Allergy Asthma Immunol. 2018;17(4):298-307.